• Skip to WISTA Sites
  • Skip to Main menu
  • Skip to Page content
WISTA Logo
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt
Search
  • de
  • en
  • WISTA Logo
  • About
    • Mission / Management
      • Company Profile
      • Team
      • Boards
      • Annual Reports
      • Invitations to tender
    • Sustainability / Diversity
    • Subsidiaries
    • Directions
  • News / Press
    • Overview
    • News
    • Events / Calendar
      • Diversity Conference Adlershof
    • Social Media Wall
    • Press
    • Magazine "Potenzial"
    • Adlershof Journal
    • Downloads
  • Services
    • All WISTA services
    • Business programmes
      • Adlershof Founder's Lab
    • Networks / Cooperations
    • Talent promotion / Recruiting
    • Event and Visitors Service
  • Projects
    • Focus Topics
    • Team Innovation
  • Sites
    • Overview
    • Technology Park Adlershof
    • Innovation Centre CHIC Charlottenburg
    • Innovation Campus FUBIC South West
    • CleanTech Business Park Marzahn
    • Business Office “Zukunftsorte”
  • Real Estate
    • Current Real Estate Offers
    • ST3AM Working Environments
    • Facility Management
  • Talents
    • Overview
    • WISTA as Employer
    • Jobs
    • Talent Promotion / Training
      • workhier! Young Academics Career Programme
      • STEM project SLE
      • Campus Club Adlershof
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt

News / Press

  • Overview
  • News
  • Events / Calendar
  • Social Media Wall
  • Press
  • Magazine "Potenzial"
  • Adlershof Journal
  • Downloads
  • Editorial Staff
  • WISTA
  • News / Press
18. March 2021

GILUPI and SCIENION announce Collaboration for the Development of Single-Cell CTC Analysis

GILUPI GmbH and SCIENION AG announced that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer patients, often causing metastasis. Their potential in the diagnosis and treatment of cancer has initiated worldwide research towards new methods for the separation and detection of CTCs from whole blood.

GILUPI is the manufacturer of the GILUPI CellCollector®, the first CE labeled medical device for in vivo CTC collection, whereas SCIENION has developed the cellenONE® dispensing technology for low volume and high accuracy single cell isolation and dispensing. The companies believe that a combination of both technologies will create a reliable and efficient workflow from patient to result.
Dr. Holger Eickhoff, CEO of SCIENION AG points out: “Efficient isolation of rare cells combined with highly accurate dispensing is the foundation for molecular profiling of metastasis causing CTCs. GILUPI is one of the pioneers in enriching CTCs and we see a strong synergy in combining both technologies.”
Dr. Christian Jurinke, CEO of GILUPI GmbH comments: “We believe that molecular analysis of single CTCs is an important cornerstone of advanced and personalized cancer treatment. The technology of SCIENION is very well suited to enable molecular profiling of CTCs on a single cell level once they are isolated from the patients.”
Under this collaboration, the companies intend to develop a workflow that allows for the isolation of CTCs directly from the bloodstream of the patient and efficiently decollates them for single cell downstream molecular analysis such as next-generation sequencing, genotyping or digital PCR. The results can then be used in determining the drug response and to provide guidance on therapy.

Contact

SCIENION AG

Volmerstraße 7b; D-12489 Berlin
Phone: +49 (0)30 - 6392 1700
support@scienion.com
www.scienion.com

 

 

Analytics Biotechnology / Environment

Related News

  • Frauke Hein © SCIENION GmbH

    SCIENION appoints Frauke Hein as CEO

    Hein to lead as SCIENION plans for long-term profitable growth
  • Visualization SCIENION Headquarters © Architekturbüro Jürgen Schlake GmbH

    SCIENION continues to grow and will build new headquarters in Berlin Adlershof

    Company acquired the leasehold for a 3,037 m² state-owned property
  • Frauke Hein © SCIENION GmbH

    SCIENION appoints Frauke Hein as CEO

    Hein to lead as SCIENION plans for long-term profitable growth
  • Visualization SCIENION Headquarters © Architekturbüro Jürgen Schlake GmbH

    SCIENION continues to grow and will build new headquarters in Berlin Adlershof

    Company acquired the leasehold for a 3,037 m² state-owned property
  • Frauke Hein © SCIENION GmbH

    SCIENION appoints Frauke Hein as CEO

    Hein to lead as SCIENION plans for long-term profitable growth
  • Visualization SCIENION Headquarters © Architekturbüro Jürgen Schlake GmbH

    SCIENION continues to grow and will build new headquarters in Berlin Adlershof

    Company acquired the leasehold for a 3,037 m² state-owned property
1 / 2
  • LinkedInshare0
  • Facebookshare0
  • WhatsAppshare0
  • E-Mail
  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Contact
  • Career
  • Press
  • Social Media Guide
Member of:
Zukunftsorte Logo